DNTH Stock Summary and Trading Ideas (Dianthus Therapeutics | NASDAQ:DNTH)

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Dianthus Therapeutics trades on the NASDAQ stock market under the symbol DNTH.

As of July 10, 2026, DNTH stock price declined to $97.60 with 819,078 million shares trading.

DNTH has a beta of 0.10, meaning it tends to be less sensitive to market movements. DNTH has a correlation of 0.00 to the broad based SPY ETF.

DNTH has a market cap of $5.34 billion. This is considered a Mid Cap stock.

Last quarter Dianthus Therapeutics reported $463,000 in Revenue and -$.85 earnings per share. This beat revenue expectation by $66,048 and exceeded earnings estimates by $.27.

The top ETF exchange traded funds that DNTH belongs to (by Net Assets): VTI, XBI, IWM, IWO, VXF.

DNTH has outperformed the market in the last year with a price return of +362.8% while the SPY ETF gained +22.2%. However, in the short term, DNTH had mixed performance relative to the market. It has underperformed in the last 3 months, returning +6.5% vs +11.3% return in SPY. But in the last 2 weeks, DNTH shares have fared better than the market returning +6.6% compared to SPY +2.8%.

DNTH support price is $95.71 and resistance is $104.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DNTH shares will trade within this expected range on the day.